Bio-Rad Acquires Stilla Technologies

Bio-Rad Laboratories, a life science research and clinical diagnostics company, has completed the acquisition of Stilla Technologies, a developer of digital PCR (dPCR) systems. The transaction was finalized following a binding offer made earlier in the year and marks a significant expansion of Bio-Rad’s digital PCR capabilities.

Bio-Rad Laboratories has completed its acquisition of Stilla Technologies, a developer of next-generation digital PCR systems. The deal, recently finalized, follows a binding offer made earlier in the year and is expected to enhance Bio-Rad’s capabilities in the biotechnology sector.

Stilla Technologies, with operations in France and the US, specializes in digital PCR instruments, consumables, and assays used in applications such as oncology diagnostics, cell and gene therapy, and infectious disease testing. The acquisition is intended to complement Bio-Rad’s existing digital PCR portfolio and support its expansion in applied research and clinical diagnostics.

Company

Logo:

Bio-Rad Laboratories


Hercules, CA
US

Company contact







Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.